Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysis aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, long-term living vessel EINDHOVEN, The Netherlands, 17 April 2024 – Xeltis, […]
BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that six companies are to receive additional financial support through its Venture House program, created to further support former Venture Lab companies through their next phase of growth. Read more…
BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that twelve new companies have entered its Venture Lab acceleration program for early-stage companies. The cohort is strategically aligned with BII’s focus on supporting innovative early-stage start-ups that can improve human and planetary health. Read more…
First patients treated with H-Guard® at the National Institute for Health and Care Research Manchester Clinical Research Facility MHRA approves continuation of Invizius’s first-in-human clinical study following a prearranged two-patient safety and performance review Study is investigating safety and tolerability of H-Guard®, a second generation complement regulator, to address serious immune system-driven complications of dialysis […]
